



# Lymphoma Working Party Educational Course

Virtual meeting  
19-21 October 2022

## WELCOME

---

EBMT is honoured to announce this year's 16th Educational Course of the Lymphoma Working Party on "Malignant Lymphomas: State of the Art with Emphasis on Cellular Therapies".

This year's course will be held fully virtual from 19-21 October 2022. For the last 15 years the course has developed into an important International Forum for young researchers and transplant physicians to closely interact with top experts in diagnostics and treatment of lymphoma focusing on transplantation and other cellular therapies.

Catherine Thieblemont, Local Organiser

Norbert Schmitz, Programme Organiser

Bertram Glass, LWP Chair

Anna Sureda, EBMT President and Chair of the Educational Subcommittee



**MINJUVI**<sup>®</sup>  
tafasitamab | 200mg  
Powder for concentrate for solution for infusion

# AIM FOR LONG-LASTING REMISSION FROM SECOND-LINE FOR YOUR ADULT PATIENTS WITH NTE R/R DLBCL<sup>1</sup>

**Find the German Mandatory text here**

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. For further information please refer to local prescribing information of the country of your residence (if available) and the MINJUVI Summary of Product Characteristics.

1. Duell J, Maddocks KJ, González-Barca E, et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. *Haematologica*. 2021;106(9):2417–2426.

NTE, non-transplant eligible

DE/MJVI/P/22/0058

Date of Preparation: October 2022

MINJUVI<sup>®</sup> (tafasitamab) is under license from MorphoSys AG



**SOLVE  
ON.**

Driving the understanding of DLBCL forward



# Lymphoma Working Party Educational Course

Virtual meeting  
19-21 October 2022

## Wednesday, 19 October 2022

14:30 – 16:00	Lymphoma Working party Scientific business meeting (Open only to EBMT members)
16:00 – 16:15	Break
16:15 – 18:00	Scientific Business Meeting
18:00	End of meeting

## Thursday, 20 October 2022

08:30 – 10:00	<b>Session I - Cellular Therapies</b> <i>Chair: Catherine Thieblemont (FR)</i>  Allogenic transplantation: Overview, background CAR T-cells: overview, background Statistics in transplantation  <i>Peter Dreger (DE)</i> <i>Sophie Caillat-Zucman (FR)</i> <i>Ariane Boumendil (FR)</i>
---------------	---

10:00 – 10:30 Break

10:30 – 12:45	<b>Session II - Hodgkin Lymphoma</b> <i>Chair: Anna Sureda (SP)</i>  Non-transplant therapies (Line 1 and news drugs in Line>1) Transplant  <i>Olivier Casasnovas (FR)</i> <i>Anna Sureda (SP)</i>
---------------	---

12:45 – 14:15 Lunch break

14:15 – 16:15	<b>Session III - Aggressive B-cell lymphoma</b> <i>Chair: Bertram Glass (DE)</i>  Non-transplant therapies (Line 1 and news drugs in Line>1) Transplant  CAR-T  Case report 1: Vinicius Araujo Soares (PY) Case Report 2: Clara Montane Carbo (SP)  <i>Hervé Tilly (FR)</i> <i>Bertram Glass (DE)</i> <i>Peter Dreger (DE)</i>
---------------	---

16:15 – 16:45 Coffee break

16:45 – 18:45	<b>Session IV - T-cell lymphoma</b> <i>Chair: Bertram Glass (DE)</i>  Non-transplant therapies (Line 1 and news drugs in Line>1) Transplant  Case report 3: Laura Korin (AR)  <i>Olivier Tournilhac (FR)</i> <i>Norbert Schmitz (DE)</i>
---------------	---

18:45 End of Meeting

## Friday, 21 October 2022

08:30 – 10:00	<b>Session V – MCL</b> <i>Chair: Catherine Thieblemont (FR)</i>  Non-transplant therapies (Line 1 and news drugs in Line>1) Transplant  <i>Olivier Hermine (FR)</i> <i>Sascha Dietrich (DE)</i>
---------------	--

10:00 – 10:30 Coffee break

10:30 – 12:30	<b>Session VI - other lymphomas</b> <i>Chair: Norbert Schmitz</i>  Transplant in indolent lymphomas New drugs and transplant in PCNSL  Case report 4: Sabina Iluta (RO) Case report 5: Tatiana Christmas (UK)  <i>Silvia Montoto (UK)</i> <i>Gerald Illerhaus (DE)</i>
---------------	--

12:30 End of the meeting



## THANK YOU TO OUR SPONSORS!

### Platinum Partner



---

### Gold Partner



---

### Silver Partner



**Miltenyi Biomedicine**



**Bristol Myers Squibb™**